Bruker [BRKR] vs Bio-Rad Laboratories [BIO] Detailed Stock Comparison
Bruker
NASDAQ
Loading...
Bio-Rad Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bruker wins in 4 metrics, Bio-Rad Laboratories wins in 15 metrics, with 0 ties. Bio-Rad Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bruker | Bio-Rad Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.46 | 27.11 | Bio-Rad Laboratories |
| Price-to-Book Ratio | 2.91 | 1.14 | Bio-Rad Laboratories |
| Debt-to-Equity Ratio | 132.75 | 19.73 | Bio-Rad Laboratories |
| PEG Ratio | 12.75 | -0.24 | Bio-Rad Laboratories |
| EV/EBITDA | 13.78 | 19.91 | Bruker |
| Profit Margin (TTM) | 2.31% | 12.50% | Bio-Rad Laboratories |
| Operating Margin (TTM) | 3.61% | 12.22% | Bio-Rad Laboratories |
| EBITDA Margin (TTM) | 3.61% | 12.22% | Bio-Rad Laboratories |
| Return on Equity | 4.07% | 4.59% | Bio-Rad Laboratories |
| Return on Assets (TTM) | 3.55% | 1.59% | Bruker |
| Free Cash Flow (TTM) | $136.00M | $266.20M | Bio-Rad Laboratories |
| 1-Year Return | -44.33% | -10.77% | Bio-Rad Laboratories |
| Price-to-Sales Ratio (TTM) | 1.52 | 3.15 | Bruker |
| Enterprise Value | $7.69B | $8.17B | Bio-Rad Laboratories |
| EV/Revenue Ratio | 2.23 | 3.20 | Bruker |
| Gross Profit Margin (TTM) | 44.88% | 52.99% | Bio-Rad Laboratories |
| Revenue per Share (TTM) | $23 | $92 | Bio-Rad Laboratories |
| Earnings per Share (Diluted) | $0.52 | $11.09 | Bio-Rad Laboratories |
| Beta (Stock Volatility) | 1.20 | 0.97 | Bio-Rad Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Bruker vs Bio-Rad Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bruker | -1.81% | 3.16% | 15.23% | -14.70% | -12.77% | -38.90% |
| Bio-Rad Laboratories | -0.97% | 2.17% | 5.13% | 18.79% | 20.65% | -7.83% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bruker | -44.33% | -34.59% | -14.84% | 99.06% | 140.98% | 687.94% |
| Bio-Rad Laboratories | -10.77% | -23.84% | -45.99% | 116.84% | 229.75% | 440.22% |
News Based Sentiment: Bruker vs Bio-Rad Laboratories
Bruker
News based Sentiment: MIXED
October presented a mixed bag for Bruker, with an earnings miss and lowered guidance countered by new orders, a strategic merger, and continued institutional investment. The conflicting signals create uncertainty, making it a significant but not overwhelmingly positive or negative month for the company.
Bio-Rad Laboratories
News based Sentiment: MIXED
October presented a mixed bag for Bio-Rad, with strategic partnerships and product launches offset by an analyst downgrade and modest revenue growth. While the company is positioning itself for growth in the precision medicine space, its recent performance and market fluctuations create uncertainty for investors, making it a cautiously optimistic investment story.
Performance & Financial Health Analysis: Bruker vs Bio-Rad Laboratories
| Metric | BRKR | BIO |
|---|---|---|
| Market Information | ||
| Market Cap | $5.24B | $8.28B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 3,829,870 | 200,440 |
| 90 Day Avg. Volume | 4,691,247 | 212,923 |
| Last Close | $35.28 | $297.72 |
| 52 Week Range | $28.53 - $65.25 | $211.43 - $387.99 |
| % from 52W High | -45.93% | -23.27% |
| All-Time High | $94.86 (Mar 18, 2024) | $832.70 (Aug 30, 2021) |
| % from All-Time High | -62.81% | -64.25% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.02% |
| Quarterly Earnings Growth | 0.00% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.13% |
| Operating Margin (TTM) | 0.04% | 0.12% |
| Return on Equity (TTM) | 0.04% | 0.05% |
| Debt to Equity (MRQ) | 132.75 | 19.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $11.89 | $263.42 |
| Cash per Share (MRQ) | $0.65 | $50.76 |
| Operating Cash Flow (TTM) | $165.90M | $534.20M |
| Levered Free Cash Flow (TTM) | $223.20M | $223.40M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Bruker vs Bio-Rad Laboratories
| Metric | BRKR | BIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.46 | 27.11 |
| Forward P/E | 12.75 | 25.81 |
| PEG Ratio | 12.75 | -0.24 |
| Price to Sales (TTM) | 1.52 | 3.15 |
| Price to Book (MRQ) | 2.91 | 1.14 |
| Market Capitalization | ||
| Market Capitalization | $5.24B | $8.28B |
| Enterprise Value | $7.69B | $8.17B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.23 | 3.20 |
| Enterprise to EBITDA | 13.78 | 19.91 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 0.97 |
| Book Value per Share (MRQ) | $11.89 | $263.42 |
Financial Statements Comparison: Bruker vs Bio-Rad Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BRKR | BIO |
|---|---|---|
| Revenue/Sales | $801.40M | $585.40M |
| Cost of Goods Sold | $410.20M | $279.40M |
| Gross Profit | $391.20M | $306.00M |
| Research & Development | $97.10M | $73.50M |
| Operating Income (EBIT) | $65.70M | $23.70M |
| EBITDA | $118.60M | $98.50M |
| Pre-Tax Income | $25.10M | $83.40M |
| Income Tax | $8.70M | $19.40M |
| Net Income (Profit) | $16.80M | $64.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BRKR | BIO |
|---|---|---|
| Cash & Equivalents | $184.20M | $521.40M |
| Total Current Assets | $2.11B | $3.04B |
| Total Current Liabilities | $1.34B | $506.60M |
| Long-Term Debt | $2.08B | $1.33B |
| Total Shareholders Equity | $1.85B | $6.68B |
| Retained Earnings | $2.42B | $7.48B |
| Property, Plant & Equipment | N/A | $681.70M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BRKR | BIO |
|---|---|---|
| Operating Cash Flow | $55.70M | $156.00M |
| Capital Expenditures | $-26.00M | $-34.40M |
| Free Cash Flow | $39.00M | $95.50M |
| Debt Repayment | $-175.60M | $-100,000 |
| Common Stock Repurchase | $-10.00M | $-101.90M |
Short Interest & Institutional Ownership Analysis
| Metric | BRKR | BIO |
|---|---|---|
| Shares Short | 12.19M | 1.11M |
| Short Ratio | 2.77 | 4.84 |
| Short % of Float | 0.17% | 0.06% |
| Average Daily Volume (10 Day) | 3,829,870 | 200,440 |
| Average Daily Volume (90 Day) | 4,691,247 | 212,923 |
| Shares Outstanding | 151.68M | 28.01M |
| Float Shares | 103.14M | 21.67M |
| % Held by Insiders | 0.32% | 0.16% |
| % Held by Institutions | 0.85% | 0.90% |
Dividend Analysis & Yield Comparison: Bruker vs Bio-Rad Laboratories
| Metric | BRKR | BIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |